Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France

This cohort study examines the progression of depressive symptoms and their associations with demographic, socioeconomic, clinical, lifestyle, and quality-of-life characteristics in women with invasive stage I to III breast cancer.

[1]  B. Levis,et al.  Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis , 2021, BMJ.

[2]  J. Ferlay,et al.  Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.

[3]  F. André,et al.  UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) , 2019, ESMO Open.

[4]  B. Avau,et al.  Systematic screening and assessment of psychosocial well-being and care needs of people with cancer. , 2016, The Cochrane database of systematic reviews.

[5]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[6]  M. Hotopf,et al.  Antidepressants for the treatment of depression in people with cancer. , 2023, The Cochrane database of systematic reviews.

[7]  L. Grassi,et al.  Depressive Spectrum Disorders in Cancer: Diagnostic Issues and Intervention. A Critical Review , 2017, Current Psychiatry Reports.

[8]  B. Johansson,et al.  Development of anxiety, depression and health-related quality of life in oncology patients without initial symptoms according to the Hospital Anxiety and Depression Scale – a comparative study , 2017, Acta oncologica.

[9]  C. Johansen,et al.  The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. , 2017, European journal of cancer.

[10]  S. Alfonsson,et al.  Socio-demographic and clinical variables associated with psychological distress 1 and 3 years after breast cancer diagnosis , 2016, Supportive Care in Cancer.

[11]  M. Quinn,et al.  Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. , 2016, Breast.

[12]  B. Johansson,et al.  Identification of Distress in Oncology Patients: A Comparison of the Hospital Anxiety and Depression Scale and a Thorough Clinical Assessment , 2016, Cancer nursing.

[13]  R. Jack,et al.  The association of mood disorders with breast cancer survival: an investigation of linked cancer registration and hospital admission data for South East England , 2015, Psycho-oncology.

[14]  John J. B. Allen,et al.  Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer , 2015, Breast Cancer Research and Treatment.

[15]  N. Avis,et al.  Trajectories of Depressive Symptoms Following Breast Cancer Diagnosis , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[16]  C. Johansen,et al.  Trajectories of distress, anxiety, and depression among women with breast cancer: Looking beyond the mean , 2015, Acta oncologica.

[17]  W. Linden,et al.  Emotional adjustment over 1 year post-diagnosis in patients with cancer: understanding and predicting adjustment trajectories , 2015, Supportive Care in Cancer.

[18]  P. Jacobsen,et al.  Depressive Symptom Trajectories During and After Adjuvant Treatment for Breast Cancer , 2014, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[19]  R. DeRubeis,et al.  Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Carvalho,et al.  Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. , 2014, Cancer treatment reviews.

[21]  P. Cuijpers,et al.  Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments , 2013, Psycho-oncology.

[22]  Anthony Fabio,et al.  Group-based trajectory analysis applications for prognostic biomarker model development in severe TBI: a practical example. , 2013, Journal of neurotrauma.

[23]  C. D’Este,et al.  Prevalence and predictors of the short-term trajectory of anxiety and depression in the first year after a cancer diagnosis: a population-based longitudinal study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Linden,et al.  Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. , 2012, Journal of affective disorders.

[25]  R. Millman,et al.  Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis , 2011, Supportive Care in Cancer.

[26]  J. Neuhaus,et al.  Identification of distinct depressive symptom trajectories in women following surgery for breast cancer. , 2011, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[27]  L. Castelli,et al.  Fast screening of depression in cancer patients: the effectiveness of the HADS. , 2011, European journal of cancer care.

[28]  Amelia M. Haviland,et al.  Group-based Trajectory Modeling Extended to Account for Nonrandom Participant Attrition , 2011 .

[29]  Paul Symonds,et al.  Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis. , 2010, Journal of affective disorders.

[30]  O. Luminet,et al.  Cognitive and anxiety symptoms in screening for clinical depression in diabetes: a systematic examination of diagnostic performances of the HADS and BDI-SF. , 2010, Journal of affective disorders.

[31]  Daniel S Nagin,et al.  Group-based trajectory modeling in clinical research. , 2010, Annual review of clinical psychology.

[32]  F. Bull,et al.  Global physical activity questionnaire (GPAQ): nine country reliability and validity study. , 2009, Journal of physical activity & health.

[33]  Tony Jung,et al.  An introduction to latent class growth analysis and growth mixture modeling. , 2008 .

[34]  G. Bonanno.  Loss, trauma, and human resilience: have we underestimated the human capacity to thrive after extremely aversive events? , 2008, The American psychologist.

[35]  K. Roeder,et al.  A SAS Procedure Based on Mixture Models for Estimating Developmental Trajectories , 2001 .

[36]  N. Aaronson,et al.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[38]  G. Huston.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.